New Data Presented at ISPOR Shows Ultrafiltration Therapy Demonstrates a Cost Savings of $3,975 Per Patient at 90 Days
May 24 2018 - 8:30AM
CHF Solutions, Inc. (Nasdaq:CHFS) announced today that a cost
analysis1 from the hospital perspective showed substantial cost
savings at 90 days when using an ultrafiltration system versus
diuretic therapy. This research was presented in a poster
session at the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) conference on Wednesday, May 23, 2018 at
the Baltimore Convention Center, Baltimore, Md.
The cost-analysis model used a decision analytic framework to
reflect treatment decisions, probabilistic outcomes, and associated
costs for treating heart failure patients suffering from fluid
overload with either ultrafiltration or intravenous
diuretics. The data presented demonstrates that although
initial hospital costs were higher in the ultrafiltration arm due
to the cost of the system itself, fluid removal by ultrafiltration
led to reduced hospital readmission days which resulted in a cost
savings of $6,148 per patient. The aggregate cost savings
with ultrafiltration over 90 days, including initial hospital
costs, were $3,975 or 14.4% per patient. Despite higher
upfront costs, ultrafiltration reduced hospital cost via
readmission rates and durations, over a 90-day period compared to
diuretic therapy.
“Limited data exists on costs associated with the use of
alternative therapies to treat patients with fluid overload,” said
John Erb, chairman and chief executive officer of CHF
Solutions. "We are encouraged by the data presented at ISPOR
which provides new supporting evidence on the potential cost
savings of ultrafiltration. Importantly, the data provides
physicians additional evidence when considering appropriate therapy
for treating fluid overload in heart failure patients that are
diuretic resistant.” About CHF
Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device
company focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy, and extended
(longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require
hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance
through science, collaboration, and innovative medical
technology. CHF Solutions is a Delaware corporation
headquartered in Minneapolis, Minnesota with wholly owned
subsidiaries in Australia and Ireland. The company
has been listed on the NASDAQ Capital Market since February
2012.
_______1 Costanzo MR, et al.
Ultrafiltration vs. Diuretics for the Treatment of Fluid Overload
in Patients with Heart Failure: A Hospital Cost Analysis. Poster
accepted for presentation at the International Society of
Pharmacoeconomics and Outcomes Research (ISPOR) International
Meeting, May 19-23, 2018, Baltimore, MD, USA
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com
-or- Bret Shapiro Managing Partner CORE IR 516-222-2560
brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024